Eagle Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Eagle Pharmaceuticals CEO'su Mike Graves, Jan2023 tarihinde atandı, in görev süresi 1.92 yıldır. şirketin hisselerinin 0.08% doğrudan sahiptir ve bu hisselerin değeri $ 5.18K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 8.1 yıldır.

Anahtar bilgiler

Mike Graves

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.9yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	8.1yrs

Son yönetim güncellemeleri

Recent updates

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29

CEO

Mike Graves (61 yo)

1.9yrs

Görev süresi

US$391,026

Tazminat

Mr. Michael Graves, also known as Mike, is Interim Principal Executive Officer of Eagle Pharmaceuticals, Inc. from 2023. He had been the Independent Chairman of Eagle Pharmaceuticals Inc. since June 2016 u...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Graves	Interim Principal Executive Officer & Executive Chairman of the Board	1.9yrs	US$391.03k	0.080% $ 5.2k
Christopher Krawtschuk	CFO and Principal Financial & Accounting Officer	less than a year	Veri yok	Veri yok
Daniel O'Connor	Executive VP	7.6yrs	Veri yok	Veri yok
Valentin Curt	Senior Vice President of Clinical Drug Development	4.1yrs	Veri yok	Veri yok
Gaozhong Zhu	Senior Vice President of Pharmaceutical Development	4.1yrs	Veri yok	Veri yok
Debra Hussain	Senior VP & Head of Commercial	2.4yrs	Veri yok	Veri yok
Reed McClung	Executive Vice President of Oncology Business Development	1.9yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: EGRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Graves	Interim Principal Executive Officer & Executive Chairman of the Board	11.1yrs	US$391.03k	0.080% $ 5.2k
Steven Ratoff	Director	17.8yrs	US$331.03k	0.21% $ 13.7k
Richard Edlin	Independent Director	7.8yrs	US$312.28k	0.17% $ 11.3k
Robert Glenning	Independent Director	8.4yrs	US$324.78k	0% $ 0
Jennifer Simpson	Lead Independent Director	5.3yrs	US$308.53k	0% $ 0
Luciana Borio	Independent Director	3.7yrs	US$308.53k	0% $ 0

8.1yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EGRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/30 22:22
Gün Sonu Hisse Fiyatı	2024/12/30 00:00
Kazançlar	2023/06/30
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Eagle Pharmaceuticals, Inc. 6 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Louise Chen	Cantor Fitzgerald & Co.
Irina Rivkind Koffler	Mizuho Securities USA LLC
David Amsellem	Piper Sandler Companies

Eagle Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes

Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Founder recently sold US$931k worth of stock

Recent updates

Eagle Pharmaceuticals to File Form 25 with the SEC to Complete the Process of Delisting of its Common Stock from the Nasdaq Global Market

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Hearings Panel of The Nasdaq Stock Market LLC Determines to Delist Eagle Pharmaceuticals' Common Stock from Nasdaq

Eagle Pharmaceuticals, Inc.(OTCPK:EGRX) dropped from NASDAQ Composite Index

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. and Curia Global, Inc. Enters into Settlement Agreement in AAA Case No. 01-23-0000-2937

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Index

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

Eagle Pharmaceuticals, Inc. announced delayed annual 10-K filing

Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes

New minor risk - Financial data availability

Investor sentiment improves as stock rises 19%

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Eagle Pharmaceuticals, Inc

Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment deteriorates as stock falls 32%

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Founder notifies of intention to sell stock

Centers for Medicare & Medicaid Services Establishes Unique, Product-Specific Billing Code and Grants Transitional Pass-Through Payment Status for Barhemsys (Amisulpride) Injection by Eagle Pharmaceuticals, Inc

Founder notifies of intention to sell stock

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Investor sentiment deteriorates as stock falls 18%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Eagle Pharmaceuticals, Inc. Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, A Novel First-In-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Growth-Defensive Index

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

New major risk - Revenue and earnings growth

Eagle Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (Qidp) and Fast-Track Designation for Cal02, Providing Five-Year Exclusivity Extension

Founder recently sold US$931k worth of stock

Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 20%

Eagle Pharmaceuticals, Inc. Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy

Consensus forecasts updated

Insufficient new directors

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Independent Director recently sold US$211k worth of stock

Insufficient new directors

U.S. Court of Appeals for the Federal Circuit Affirms the U.S. District Court for the District of Delaware’s Decision That Eagle Pharmaceuticals, Inc.'s Vasopressin Product Does Not Infringe on Any of the Patents Asserted by Par Pharmaceutical, Inc

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Consensus revenue estimates fall by 21%

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Price target decreased to US$43.00

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Eagle Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Michael Moran Separates as Executive Vice President, Chief Commercial Officer of Eagle Pharmaceuticals, Inc

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc., Annual General Meeting, Jul 28, 2022

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) completed the acquisition of Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders.

Eagle Pharmaceuticals, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, A Beta-1 Adrenergic Blocker

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 20% undervalued